{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:44:45Z","timestamp":1764225885724,"version":"3.46.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Monoclonal antibodies have been widely used in the fight against infectious diseases and are recommended for postexposure prophylaxis (PEP) of the rabies virus because of their advantages of easy supply, low cost, and high efficacy. To maximize treatment efficiency and minimize side effects, the binding affinity of isolated mAbs requires further enhancement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we developed a high-throughput saturation mutagenesis platform to improve the neutralizing activity of a preclinical antirabies mAb. We generated a system displaying antibodies on mammalian cell surfaces to block the invasion of the pseudotyped rabies virus. Saturation mutagenesis was performed on the complementarity-determining regions (CDRs) of the parental mAb, followed by screening for mutant mAbs with greater neutralizing activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified several mutations, including S5A, K18F, and N29C, that increased the neutralizing activity of the mAbs against six fixed strains of rabies virus, with average improvements of 4.92, 3.45, and 4.99 times, respectively. Furthermore, mAbs with the combined mutations S4I-P35S-N76D and S14H-T32N demonstrated significantly improved neutralizing activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We established a high-throughput saturation mutagenesis platform for antibody affinity modification, enhancing the anti-infection ability of the antirabies NC08 antibody through single-point and multiple-point mutants. This platform is also applicable for optimizing other mAbs in preclinical stages in terms of neutralizing activity and achieving broad-spectrum activity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1722831","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:30:57Z","timestamp":1764225057000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Establishment of rapid saturation mutagenesis and screening methods for improving the neutralizing activity of monoclonal antibodies"],"prefix":"10.3389","volume":"16","author":[{"given":"Xi","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenchen","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanru","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youchun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.5455\/OVJ.2023.v13.i11.1","article-title":"Tracking lethal threat: in-depth review of rabies","volume":"13","author":"Khairullah","year":"2023","journal-title":"Open Vet J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00641-7","article-title":"Human rabies despite post-exposure prophylaxis: a systematic review of fatal breakthrough infections after zoonotic exposures","volume":"23","author":"Whitehouse","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.02.075","article-title":"Cost-effectiveness of rabies post-exposure prophylaxis in the context of very low rabies risk: A decision-tree model based on the experience of France","volume":"33","author":"Ribadeau Dumas","year":"2015","journal-title":"Vaccine"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2081024","DOI":"10.1080\/21645515.2022.2081024","article-title":"Safety and clinical efficacy of human rabies immunoglobulin in post exposure prophylaxis for category III animal exposures","volume":"18","author":"Haradanhalli","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2026713","DOI":"10.1080\/21645515.2022.2026713","article-title":"Advances in the progress of monoclonal antibodies for rabies","volume":"18","author":"Fan","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.11.004","article-title":"Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline","author":"Sparrow","year":"2019","journal-title":"Vaccine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12033-011-9478-3","article-title":"Attainment of 15-fold higher affinity of a Fusarium-specific single-chain antibody by directed molecular evolution coupled to phage display","volume":"52","author":"Liu","year":"2012","journal-title":"Mol Biotechnol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/biot.200600205","article-title":"Method for generation of human hyperdiversified antibody fragment library","volume":"2","author":"Mondon","year":"2007","journal-title":"Biotechnol J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e1011119","DOI":"10.1371\/journal.ppat.1011119","article-title":"High-throughput saturation mutagenesis generates a high-affinity antibody against SARS-CoV-2 variants using protein surface display assay on a human cell","volume":"19","author":"Yang","year":"2023","journal-title":"PloS Pathog"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2021.11.010","article-title":"Deep mutational scanning for therapeutic antibody engineering","volume":"43","author":"Hanning","year":"2022","journal-title":"Trends Pharmacol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2079426","article-title":"ACE2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes SARS-CoV-2 and its prevalent variants","volume":"11","author":"Wang","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2020.01.152","article-title":"Production and characterization of a single-chain variable fragment antibody from a site-saturation mutagenesis library derived from the anti-Cry1A monoclonal antibody","volume":"149","author":"Dong","year":"2020","journal-title":"Int J Biol Macromol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11071133","article-title":"Development of a bioluminescent imaging mouse model for SARS-coV-2 infection based on a pseudovirus system","volume":"11","author":"Wu","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","article-title":"The impact of mutations in SARS-coV-2 spike on viral infectivity and antigenicity","volume":"182","author":"Li","year":"2020","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-1053-3_1","article-title":"Error-prone PCR and effective generation of gene variant libraries for directed evolution","volume":"1179","author":"Copp","year":"2014","journal-title":"Methods Mol Biol"},{"key":"B16","article-title":"Efficient site-directed saturation mutagenesis using degenerate oligonucleotides","volume":"18","author":"Steffens","year":"2007","journal-title":"J Biomol Tech"},{"key":"B17","doi-asserted-by":"publisher","first-page":"10654","DOI":"10.1038\/srep10654","article-title":"Economical analysis of saturation mutagenesis experiments","volume":"5","author":"Acevedo-Rocha","year":"2015","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2174\/1570162X113116660062","article-title":"Antibody-dependent enhancement and the risk of HIV infection","volume":"11","author":"Gorlani","year":"2013","journal-title":"Curr HIV Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.1963","article-title":"Current status on the development of pseudoviruses for enveloped viruses","volume":"28","author":"Li","year":"2018","journal-title":"Rev Med Virol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1743767","article-title":"Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2","volume":"9","author":"Nie","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.cell.2023.02.001","article-title":"A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike","volume":"186","author":"Dadonaite","year":"2023","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2006.05.037","article-title":"Identification of cysteinylation of a free cysteine in the Fab region of a recombinant monoclonal IgG1 antibody using Lys-C limited proteolysis coupled with LC\/MS analysis","volume":"355","author":"Gadgil","year":"2006","journal-title":"Anal Biochem"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21014","article-title":"Removal of cysteinylation from an unpaired sulfhydryl in the variable region of a recombinant monoclonal IgG1 antibody improves homogeneity, stability, and biological activity","volume":"97","author":"Banks","year":"2008","journal-title":"J Pharm Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1160179","article-title":"Cysteinylation of a monoclonal antibody leads to its inactivation","volume":"8","author":"McSherry","year":"2016","journal-title":"MAbs"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1722831\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:30:59Z","timestamp":1764225059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1722831\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":24,"alternative-id":["10.3389\/fimmu.2025.1722831"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1722831","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"article-number":"1722831"}}